期刊
NEUROBIOLOGY OF DISEASE
卷 157, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2021.105427
关键词
Neurodegeneration; Triplet nucleotide repeat diseases; Bioenergetics; Fibroblasts; Brain; Antioxidants; Unfolded protein response; NRF2; Phytochemicals
资金
- National Institutes of Health [HD036071]
CGG expansions in the 5'-untranslated region of the FMR1 gene increase the risk of FXTAS, and sulforaphane has shown beneficial effects on pathways related to brain function in fibroblasts from FXTAS-affected subjects, paving the way for potential clinical studies in treating FXTAS.
CGG expansions between 55 and 200 in the 5 '-untranslated region of the fragile-X mental retardation gene (FMR1) increase the risk of developing the late-onset debilitating neuromuscular disease Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). While the science behind this mutation, as a paradigm for RNA-mediated nucleotide triplet repeat expansion diseases, has progressed rapidly, no treatment has proven effective at delaying the onset or decreasing morbidity, especially at later stages of the disease. Here, we demonstrated the beneficial effect of the phytochemical sulforaphane (SFN), exerted through NRF2-dependent and independent manner, on pathways relevant to brain function, bioenergetics, unfolded protein response, proteosome, antioxidant defenses, and iron metabolism in fibroblasts from FXTAS-affected subjects at all disease stages. This study paves the way for future clinical studies with SFN in the treatment of FXTAS, substantiated by the established use of this agent in clinical trials of diseases with NRF2 dysregulation and in which age is the leading risk factor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据